Celgene

Celgene is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies for cancer, inflammatory diseases, and immune system disorders. The company was founded in 1986 by David Stirling and Sol Barer and is headquartered in Summit, New Jersey. Celgene has collaborated with various organizations, including Bristol-Myers Squibb, Novartis, and the National Cancer Institute, to advance its research and development efforts. The company's work has been recognized by Fortune magazine as one of the Fastest-Growing Companies in the United States.

● History

Celgene's history began with its founding in 1986 by David Stirling and Sol Barer, with the goal of developing innovative therapies for cancer and other diseases. The company's early research focused on the development of thalidomide, a drug that was initially developed in the 1950s by Grünenthal but was later withdrawn from the market due to its teratogenic effects. Celgene's work on thalidomide led to its approval by the US Food and Drug Administration (FDA) in 1998 for the treatment of multiple myeloma, a type of blood cancer. The company has also collaborated with Johnson & Johnson and Pfizer on various research and development projects. In 2019, Celgene was acquired by Bristol-Myers Squibb for $74 billion, making it one of the largest pharmaceutical deals in history, involving companies such as Gilead Sciences and Amgen.

● Products

Celgene's product portfolio includes several innovative therapies for the treatment of cancer, inflammatory diseases, and immune system disorders. The company's flagship product is Revlimid (lenalidomide), a drug used to treat multiple myeloma and myelodysplastic syndromes. Other key products include Pomalyst (pomalidomide) and Thalomid (thalidomide), which are also used to treat multiple myeloma. Celgene has also developed Otezla (apremilast), a drug used to treat psoriasis and psoriatic arthritis, in collaboration with AstraZeneca and the University of California, San Francisco. The company's products have been approved by regulatory agencies such as the European Medicines Agency and the US Food and Drug Administration.

● Research and Development

Celgene's research and development efforts focus on the discovery and development of innovative therapies for cancer, inflammatory diseases, and immune system disorders. The company has established collaborations with various academic and research institutions, including the University of Oxford, Harvard University, and the National Institutes of Health. Celgene's research has led to the development of several promising pipeline candidates, including luspatercept, a drug being developed in collaboration with Acceleron Pharma for the treatment of beta-thalassemia and myelodysplastic syndromes. The company has also partnered with OncoMed Pharmaceuticals and Agios Pharmaceuticals to develop new therapies for cancer.

● Acquisitions and Partnerships

Celgene has established several strategic partnerships and acquisitions to advance its research and development efforts. In 2019, the company was acquired by Bristol-Myers Squibb for $74 billion, creating a leading global biopharmaceutical company. Celgene has also partnered with AbbVie and Biogen to develop new therapies for cancer and inflammatory diseases. The company has acquired several biotechnology companies, including Receptos and EngMab, to expand its pipeline and capabilities. Celgene has also collaborated with Roche and Merck & Co. on various research and development projects.

● Corporate Affairs

Celgene is headquartered in Summit, New Jersey, and has operations in several countries, including the United States, Europe, and Asia. The company is led by a team of experienced executives, including Mark Alles, who served as the company's CEO until its acquisition by Bristol-Myers Squibb. Celgene has been recognized as one of the Best Places to Work by Fortune magazine and has received several awards for its corporate social responsibility initiatives, including the Corporate Citizenship Award from the National Association of Manufacturers. The company has also partnered with Microsoft and IBM to develop innovative technologies and solutions for the biopharmaceutical industry. Category:Biotechnology companies